CN109843872A - 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 - Google Patents

作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 Download PDF

Info

Publication number
CN109843872A
CN109843872A CN201880002070.7A CN201880002070A CN109843872A CN 109843872 A CN109843872 A CN 109843872A CN 201880002070 A CN201880002070 A CN 201880002070A CN 109843872 A CN109843872 A CN 109843872A
Authority
CN
China
Prior art keywords
compound
alkyl
naphthenic base
heteroaryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880002070.7A
Other languages
English (en)
Other versions
CN109843872B (zh
Inventor
张汉承
叶向阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shijiazhuang Pharmaceutical Group Ouyi Pharma Co Ltd
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Hangzhou Innogate Pharma Co Ltd
Original Assignee
Hangzhou Innogate Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Innogate Pharma Co Ltd filed Critical Hangzhou Innogate Pharma Co Ltd
Publication of CN109843872A publication Critical patent/CN109843872A/zh
Application granted granted Critical
Publication of CN109843872B publication Critical patent/CN109843872B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)

Abstract

本发明提供了一种作为IDO抑制剂和/或IDO‑HDAC双重抑制剂的多环化合物，具体地，本发明提供了一种如下式(I)所示的化合物，其中，各基团的定义如说明书中所述。所述的化合物具有IDO抑制活性或IDO‑HDAC双重抑制活性，可以用于预防或治疗与IDO和/或IDO‑HDAC活性或表达量相关的疾病。同时本发明专利所述化合物可以和免疫抗肿瘤的抗体如PD‑1和PD‑L1等进行联合用药，这样的联合用药能够大大提高抗体的抗肿瘤的应答率，拓宽所要治疗的肿瘤的种类。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201880002070.7A 2017-09-20 2018-09-20 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 Active CN109843872B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201710854520 2017-09-20
CN2017108545202 2017-09-20
CN201711397888 2017-12-21
CN2017113978887 2017-12-21
CN2018101193245 2018-02-06
CN201810119324 2018-02-06
PCT/CN2018/106768 WO2019057123A1 (zh) 2017-09-20 2018-09-20 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物

Publications (2)

Publication Number Publication Date
CN109843872A true CN109843872A (zh) 2019-06-04
CN109843872B CN109843872B (zh) 2022-08-30

Family

ID=65810056

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880002070.7A Active CN109843872B (zh) 2017-09-20 2018-09-20 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物

Country Status (5)

Country Link
US (1) US11266640B2 (zh)
EP (1) EP3686196A4 (zh)
JP (1) JP2020534336A (zh)
CN (1) CN109843872B (zh)
WO (1) WO2019057123A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110950842A (zh) * 2018-09-27 2020-04-03 深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
CN112004790A (zh) * 2018-04-09 2020-11-27 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2587457B (en) 2017-08-04 2022-06-01 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
US11180497B2 (en) * 2017-10-18 2021-11-23 Angex Pharmaceutical, Inc. Cyclic compounds as immunomodulating agents
CN110156674A (zh) * 2018-02-13 2019-08-23 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
KR102596598B1 (ko) 2018-04-26 2023-11-03 화이자 인코포레이티드 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체
KR20210135241A (ko) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
EP3920928A4 (en) 2019-02-06 2022-09-28 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
CN111909107B (zh) * 2019-05-10 2023-02-03 药康众拓(江苏)医药科技有限公司 Ido/hdac双重抑制剂及其药物组合物和应用
WO2021096542A1 (en) * 2019-11-12 2021-05-20 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in the treatment of cancer and methods thereof

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023844A2 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
CN1950082A (zh) * 2004-03-03 2007-04-18 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
CN101163696A (zh) * 2005-05-19 2008-04-16 色品疗法有限公司 组蛋白脱乙酰酶抑制剂
WO2009058347A1 (en) * 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Aryl-substituted bridged or fused diamines as modulators of leukotriene a4 hydrolase
WO2009071553A1 (en) * 2007-12-04 2009-06-11 Palumed S.A. New therapeutic uses of dual molecules containing a peroxide derivative
US20090192141A1 (en) * 2004-04-29 2009-07-30 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
CN102459189A (zh) * 2009-05-12 2012-05-16 赛诺菲 5-元杂环化合物环戊二烯并[c]吡咯基烷基氨基甲酸酯衍生物、其制备、及其治疗用途
WO2013091539A1 (zh) * 2011-12-21 2013-06-27 江苏恒瑞医药股份有限公司 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用
CN103687855A (zh) * 2011-06-02 2014-03-26 英特维特国际股份有限公司 咪唑衍生物
WO2014139328A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
WO2016073770A1 (en) * 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents
WO2016115463A1 (en) * 2015-01-15 2016-07-21 Whitehead Institute For Biomedical Research Inhibitors of phosphoglycerate dehydrogenase (phgdh) and uses thereof
WO2017007756A1 (en) * 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
CN106478607A (zh) * 2015-08-28 2017-03-08 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
WO2017044434A1 (en) * 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
WO2017097671A1 (de) * 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung
CN106916164A (zh) * 2017-03-06 2017-07-04 中国药科大学 噻唑并嘧啶酮类ido1抑制剂及其医药用途
CN106999450A (zh) * 2014-11-05 2017-08-01 弗莱塞斯生物科学公司 免疫调节剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536291A (ja) * 1997-08-15 2002-10-29 ファイザー・プロダクツ・インク ２−（４−アリール又はヘテロアリール−ピペラジン−１−イルメチル）−１ｈ−インドール誘導体
MY145722A (en) * 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
WO2003070244A1 (en) * 2002-02-22 2003-08-28 Abbott Laboratories Antagonist of melanin concentrating hormone and their uses
BR112015023187A2 (pt) * 2013-03-14 2017-07-18 Abbvie Inc inibidores de pirrolo[2,3 - b] piridina cdk9 kinase
US9637450B2 (en) * 2013-03-14 2017-05-02 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
NZ721617A (en) * 2014-02-03 2018-01-26 Cadila Healthcare Ltd Heterocyclic compounds
RU2016149812A (ru) 2014-06-06 2018-07-17 Флексус Байосайенсиз, Инк. Иммунорегулирующие средства
WO2016073738A2 (en) 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents
CA2991224A1 (en) 2015-07-02 2017-01-05 buildpulse, Inc. Advanced identification and classification of sensors and other points in a building automation system
CN107001271B (zh) 2015-08-07 2019-05-10 江苏恒瑞医药股份有限公司 羟基脒类衍生物、其制备方法及其在医药上的应用
WO2017192744A1 (en) 2016-05-04 2017-11-09 Motif BioSciences Inc. Systems and methods for treating bacterial infection
KR20190003686A (ko) 2016-05-04 2019-01-09 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
CN109414421A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
CN110540521A (zh) * 2018-05-28 2019-12-06 北京诺诚健华医药科技有限公司 八氢戊搭烯类化合物、其制备方法及其在医药学上的应用

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1950082A (zh) * 2004-03-03 2007-04-18 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
US20090192141A1 (en) * 2004-04-29 2009-07-30 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006023844A2 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
CN101163696A (zh) * 2005-05-19 2008-04-16 色品疗法有限公司 组蛋白脱乙酰酶抑制剂
WO2009058347A1 (en) * 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Aryl-substituted bridged or fused diamines as modulators of leukotriene a4 hydrolase
WO2009071553A1 (en) * 2007-12-04 2009-06-11 Palumed S.A. New therapeutic uses of dual molecules containing a peroxide derivative
CN102459189A (zh) * 2009-05-12 2012-05-16 赛诺菲 5-元杂环化合物环戊二烯并[c]吡咯基烷基氨基甲酸酯衍生物、其制备、及其治疗用途
CN103687855A (zh) * 2011-06-02 2014-03-26 英特维特国际股份有限公司 咪唑衍生物
WO2013091539A1 (zh) * 2011-12-21 2013-06-27 江苏恒瑞医药股份有限公司 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用
WO2014139328A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
WO2016073770A1 (en) * 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents
CN106999450A (zh) * 2014-11-05 2017-08-01 弗莱塞斯生物科学公司 免疫调节剂
WO2016115463A1 (en) * 2015-01-15 2016-07-21 Whitehead Institute For Biomedical Research Inhibitors of phosphoglycerate dehydrogenase (phgdh) and uses thereof
WO2017007756A1 (en) * 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
CN106478607A (zh) * 2015-08-28 2017-03-08 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
WO2017044434A1 (en) * 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
WO2017097671A1 (de) * 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Substituierte perhydropyrrolo[3,4-c]pyrrol-derivate und ihre verwendung
CN106916164A (zh) * 2017-03-06 2017-07-04 中国药科大学 噻唑并嘧啶酮类ido1抑制剂及其医药用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER L. CIOFFI等: "Design，Synthesis，and Evaluation of Nonretinoid Retinol Binding Protein 4 Antagonists for the Potential Treatment of Atrophic Age-Related Macular Degeneration and Stargardt Disease", 《J. MED. CHEM.》 *
JOSEPH J. TOPCZEWSKI等: "Palladium-Catalyzed Transannular C–H Functionalization of Alicyclic Amines", 《NATURE》 *
REG: "STN检索记录", 《STN检索》 *
REGISTRY: "RN：1385048-43-0", 《STN检索》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112004790A (zh) * 2018-04-09 2020-11-27 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
CN110950842A (zh) * 2018-09-27 2020-04-03 深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
CN110950842B (zh) * 2018-09-27 2023-06-20 深圳微芯生物科技股份有限公司 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物

Also Published As

Publication number Publication date
EP3686196A1 (en) 2020-07-29
EP3686196A4 (en) 2021-03-31
JP2020534336A (ja) 2020-11-26
WO2019057123A1 (zh) 2019-03-28
US11266640B2 (en) 2022-03-08
US20200276180A1 (en) 2020-09-03
CN109843872B (zh) 2022-08-30

Similar Documents

Publication Publication Date Title
CN109843872A (zh) 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
CN113651814B (zh) Kras突变蛋白抑制剂
TWI790264B (zh) 雜環化合物及其用途
CN113286794B (zh) Kras突变蛋白抑制剂
JP6877407B2 (ja) Ｎｔｒｋ関連障害の治療に有用な化合物および組成物
RU2679131C2 (ru) Производное 1,3-бензодиоксола
CN105916855B (zh) 作为酪蛋白激酶1d/e抑制剂的取代的4，5，6，7-四氢吡唑并[1，5-a]吡嗪衍生物
CN107438611B (zh) 稠环化合物、其药物组合物及应用
CN109890797B (zh) 可用作抗癌剂的取代的碳核苷衍生物
CN105308038B (zh) Zeste增强子同源物2的抑制剂
WO2021129824A1 (zh) 新型K-Ras G12C抑制剂
CN108699032A (zh) 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途
WO2019158019A1 (zh) 嘧啶并环化合物及其制备方法和应用
CN108884029A (zh) Lsd1抑制剂
WO2022214102A1 (zh) 作为kras g12d抑制剂的杂环化合物
CN108368090A (zh) 作为免疫调节剂的化合物
CN107207514A (zh) 稠环杂芳基化合物及其作为trk抑制剂的用途
CN107106559A (zh) 自分泌运动因子的取代的螺环抑制剂
CN110156786A (zh) 嘧啶并环化合物及其制备方法和应用
CN110105346A (zh) 选择性取代的喹啉化合物
WO2020061375A1 (en) Antibacterial compounds
WO2022268230A1 (zh) 作为kif18a抑制剂的化合物
IL179257A (en) Cyclopenta[b]benzofuran derivatives and the utilization thereof
CA3075880A1 (en) Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
WO2023025116A1 (zh) 杂环类衍生物、其制备方法及其医药上的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20191226

Address after: 311121 18 stories south of No. 4 Building, 1500 Wenyi West Road, Cangqian Street, Yuhang District, Hangzhou City, Zhejiang Province

Applicant after: HANGZHOU INNOGATE PHARMA Co.,Ltd.

Applicant after: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd.

Applicant after: CSPC PHARMACEUTICAL GROUP OUYI PHARMA Co.,Ltd.

Address before: 311121 353, room 4, 20 Longtan Road, Cang Qian street, Yuhang District, Hangzhou, Zhejiang.

Applicant before: HANGZHOU INNOGATE PHARMA Co.,Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005661

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant